{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DPX-Survivac",
    "query": {
      "intervention": "DPX-Survivac"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T17:22:33.517Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02785250",
      "title": "Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Epithelial Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat (INCB024360)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 85,
      "start_date": "2016-04",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Augusta, Georgia • New York, New York + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02785250"
    },
    {
      "nct_id": "NCT03836352",
      "title": "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Non-small Cell Lung Cancer",
        "Bladder Cancer",
        "Microsatellite Instability-High"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2018-12-21",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03836352"
    },
    {
      "nct_id": "NCT05243524",
      "title": "Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Maveropepimut-S",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2022-08-05",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05243524"
    },
    {
      "nct_id": "NCT04895761",
      "title": "Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Letrozole 2.5mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        },
        {
          "name": "XRT 10Gy x2",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-10",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895761"
    },
    {
      "nct_id": "NCT03332576",
      "title": "Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DPX-Survivac(Aqueous)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2013-08-23",
      "completion_date": "2019-09-09",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 2,
      "location_summary": "Mineola, New York • New York, New York",
      "locations": [
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332576"
    },
    {
      "nct_id": "NCT04920617",
      "title": "DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Diffuse Large B-cell Lymphoma",
        "Refractory Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "CPA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2021-06-18",
      "completion_date": "2025-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 17,
      "location_summary": "Fountain Valley, California • Boca Raton, Florida • Hollywood, Florida + 13 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04920617"
    },
    {
      "nct_id": "NCT01416038",
      "title": "Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "BIOLOGICAL"
        },
        {
          "name": "low dose cyclophosphamide (oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2011-12",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-09-04T17:22:33.517Z",
      "location_count": 5,
      "location_summary": "Buffalo, New York • Mineola, New York • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416038"
    }
  ]
}